Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecula...
Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy
CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC ( Prof Andrea Sartore-Bianchi - Ospedale Niguarda, Milan, Italy )
10 Jun 2021
CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC
Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA
CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC ( Dr Ferdinandos Skoulidis - MD Anderson Cancer Center, Houston, USA )
9 Jun 2021
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and con...
Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain
LEAP-004: Lenvatinib + pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor ( Dr Ana Arance - Hospital Clínic de Barcelona, Barcelona, Spain )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 3
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC
Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany
PANAMA: Maintenance 5FU/LV plus panitumumab or 5FU/LV alone in RAS wildtype mCRC ( Prof Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 2
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
OncoAlert and ecancer ASCO roundup - Day 1
Dr Gil Morgan - Skåne University Hospital in Lund, Sweden
OncoAlert and ecancer ASCO roundup - Day 1 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )
8 Jun 2021
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve...
Dr Joshua Sabari and Dr Anna Minchom
Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC ( Dr Joshua Sabari and Dr Anna Minchom )
8 Jun 2021
Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction...
Prof Daniel Catenacci - University of Chicago, Chicago, USA
Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma ( Prof Daniel Catenacci - University of Chicago, Chicago, USA )
5 Jun 2021
mCRPC: Latest developments in diagnostics and combination therapies
Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor
mCRPC: Latest developments in diagnostics and combination therapies ( Dr Eleni Efstathiou, Prof Fred Saad and Prof Oliver Sartor )
4 Jun 2021
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally ad...
Dr Terence Friedlander - UCSF, San Francisco, USA
Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma ( Dr Terence Friedlander - UCSF, San Francisco, USA )
4 Jun 2021
Olaparib improves disease-free survival in high-risk early-stage HER2-negative b...
Prof Andrew Tutt - Institute of Cancer Research, London, UK
Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations ( Prof Andrew Tutt - Institute of Cancer Research, London, UK )
4 Jun 2021